BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 30088177)

  • 21. Clinical subtypes and prognosis in breast cancer according to parity: a nationwide study in Korean Breast Cancer Society.
    Park S; Moon BI; Oh SJ; Lee HB; Seong MK; Lee S; Byun KD; Jung SP; Bae SY
    Breast Cancer Res Treat; 2019 Feb; 173(3):679-691. PubMed ID: 30390214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
    Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Debled M; Mouret-Reynier MA; Goncalves A; Dalenc F; Delaloge S; Campone M; Augereau P; Ferrero JM; Levy C; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Chevrot M; Pasquier D; Bachelot T
    Br J Cancer; 2019 Dec; 121(12):991-1000. PubMed ID: 31719684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced risk of axillary lymphatic spread in triple-negative breast cancer.
    Holm-Rasmussen EV; Jensen MB; Balslev E; Kroman N; Tvedskov TF
    Breast Cancer Res Treat; 2015 Jan; 149(1):229-36. PubMed ID: 25488719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New developments in breast cancer prognosis: molecular predictors of treatment response and survival.
    Foo EM; Boost MV; Wong AS; Loo WT; Chow LW; Chow CY
    Int J Biol Markers; 2013 Jun; 28(2):131-40. PubMed ID: 23709349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
    Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
    Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Locoregional recurrence by molecular subtype after multicatheter interstitial accelerated partial breast irradiation: Results from the Pooled Registry Of Multicatheter Interstitial Sites research group.
    Anderson BM; Kamrava M; Wang PC; Chen P; Demanes DJ; Hayes JK; Kuske RR
    Brachytherapy; 2016; 15(6):788-795. PubMed ID: 27743957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
    Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
    Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pregnancy associated breast cancer (PABC): Report from a gestational cancer registry from a tertiary cancer care centre, India.
    Bajpai J; Simha V; Shylasree TS; Sarin R; Pathak R; Popat P; Mokal S; Dandekar S; Bhansal V; Ghosh J; Nair N; Gulia S; Rath S; Joshi S; Wadasadawala T; Sheth T; Parmar V; Banavali SD; Badwe RA; Gupta S
    Breast; 2021 Apr; 56():88-95. PubMed ID: 33640524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
    Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database.
    Kim YJ; Kim JS; Kim IA
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1803-1816. PubMed ID: 29971531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor subtypes and survival in male breast cancer.
    Leone J; Freedman RA; Lin NU; Tolaney SM; Vallejo CT; Leone BA; Winer EP; Leone JP
    Breast Cancer Res Treat; 2021 Aug; 188(3):695-702. PubMed ID: 33770314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2- breast cancer and is associated with inferior outcomes.
    Mills M; Liveringhouse C; Lee F; Nanda RH; Ahmed KA; Washington IR; Thapa R; Fridley BL; Blumencranz P; Extermann M; Loftus L; Balducci L; Diaz R
    J Geriatr Oncol; 2021 Mar; 12(2):219-226. PubMed ID: 32859560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice.
    Lim YJ; Lee SW; Choi N; Kwon J; Eom KY; Kang E; Kim EK; Kim SW; Kim JH; Kim YJ; Kim SH; Park SY; Kim JS; Kim IA
    Breast Cancer Res Treat; 2017 Jun; 163(3):555-563. PubMed ID: 28315066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic copy number alterations as biomarkers for triple negative pregnancy-associated breast cancer.
    Suelmann BBM; Rademaker A; van Dooijeweert C; van der Wall E; van Diest PJ; Moelans CB
    Cell Oncol (Dordr); 2022 Aug; 45(4):591-600. PubMed ID: 35792986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.